SWOG clinical trial number
CTSU/CALGB 51101
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma.
Closed
Abbreviated Title
Randomized Ph II of myeloablative vs. non-myeloablative consolidation in CNS b-cell lymphoma
Activated
07/01/2012
Closed
05/02/2017
Participants
CTSU
Research committees
Lymphoma
Treatment
Etoposide
Filgrastim
GM-CSF
Leucovorin + 5-FU
Methotrexate
Rituximab
Temozolomide
Thiotepa
Carmustine
Cytarabine
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
14%
Open
Phase